Slide 1: Letter to stock exchanges: Investor / Analysts Presentation
November 9, 2023 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Phiroz Jeejeebhoy Towers, MUMBAI -400 051 25th floor, Dalal Street, MUMBAI -400 001 Company Code No. AUROPHARMA Company
Slide 2: Aurobindo Pharma Limited Earnings Presentation Q2FY24
Aurobindo Pharma Limited Earnings Presentation Q2FY24
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any par
Slide 4: Table of Content
Table of Content 04 Q2FY24 Business & Financial Highlights 10 Update on biosimilars 12 Financial Summary 13 15 Filings Snapshot 3
Slide 5: Q2FY24 Business & Financial Highlights
Q2FY24 Business & Financial Highlights 4
Slide 6: Quarterly Performance – Q2 FY24
Quarterly Performance – Q2 FY24 Revenue (Rs Crore) US Revenue excluding Puerto Rico (US$ Mn) 7,219 409 6,851 372 359 382 6,236 6,407 6,473 355 5,739 313 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 EBITDA (Rs Crore) Net Debt to Equity 1,403 1,151 965 954 1,002
Slide 7: Consolidated Financial & Business Highlights – Q2 FY24
Consolidated Financial & Business Highlights – Q2 FY24 Revenue from operations at Rs 7,219 crore, an increase of 25.8% YoY | US revenues (excl. Puerto Rico) at US$ 409 Mn EBITDA before Forex and Other income at Rs 1,403 crore | EBITDA margin is at 19.4% Net Profit after minority interest is at Rs 75
Slide 8: Consolidated Operational Performance
Consolidated Operational Performance ₹ Cr Q2FY24 Q2FY23 Y-o-Y (%) Q1FY24 Q-o-Q (%) USA** 3,385 2,495 35.7% 3,137 7.9% Europe 1,769 1,516 16.7% 1,837 -3.7% Growth Markets* 564 452 24.7% 475 18.6% ARV 250 164 52.1% 201^ 24.4% Total Formulations 5,968 4,627 29.0% 5,650 5.6% Betalactum 816 636 28.4% 719
Slide 9: US Formulations Business Performance Highlights (Excluding Puerto Rico)
US Formulations Business Performance Highlights (Excluding Puerto Rico) Revenue (US$ Mn) Commentary 450 409 400 382 350 313 • US revenue in Q2FY24 increased by 31% YoY and 7% QoQ to 300 250 USD 409 Mn, accounting for 47% of consolidated revenue 200 150 • Eugia revenue in the US which includes inject
Slide 10: Europe, ARV, Growth Markets, API Business Revenues & Performance Highlights
Europe, ARV, Growth Markets, API Business Revenues & Performance Highlights Europe (EUR Mn) Growth Markets (US$ Mn) ARV (US$ Mn) API (Rs Crore) 1,166 68 205 197 1,033 189 30 57 58 969 24 21 Q2FY23 Q1FY24 Q2FY24 Q2FY23 Q1FY24* Q2FY24 Q2FY23 Q1FY24* Q2FY24 Q2FY23 Q1FY24 Q2FY24 Growth Markets posted re
Slide 11: Update on Biosimilars
Update on Biosimilars 10
Slide 12: Advancing our Oncology and Immunology Biosimilar Programs - Biologics
Advancing our Oncology and Immunology Biosimilar Programs -Biologics • CuraTeQ Biologics is a wholly owned subsidiary of Aurobindo Pharma Ltd • Our business strategy primarily focuses on developing Oncology and Immunology biosimilars • Our broader pipeline of 14 biosimilars positions CuraTeQ uniquel
Slide 13: Financial Summary
Financial Summary 12
Slide 14: Consolidated Profit & Loss Statement (as reported)
Consolidated Profit & Loss Statement (as reported) Rs Cr Q2FY24 Q2FY23 YoY Chg. (%) Q1FY24 QoQ Chg. (%) Revenue from operations 7,219 5,739 25.8% 6,851 5.4% Gross Profit 3,983 3,171 25.6% 3,696 7.8% Gross Margin 55.2% 55.3% -9 bps 53.9% 122 bps Overheads -2,579 -2,334 10.5% -2,544 1.4% EBITDA (befor
Slide 15: Debt profile
Debt profile Gross debt (US$ Mn) Debt as on (INR Cr) Mar-20 Mar-21 Mar-22 Mar-23 Sep-23 Closing Rate (INR/USD) 75.665 73.110 75.793 82.170 83.045 732 674 313 592 752 Fx Loan restated in INR 5,549 4,929 2,223 4,638 4,832 Rupee Loan 17 44 150 224 1,414 Gross Debt 5,566 4,972 2,373 4,862 6,246 180 110
Slide 16: Filing Snapshot
Filing Snapshot 15
Slide 17: US ANDA Filings Snapshot as on 30th September 2023
US ANDA Filings Snapshot as on 30th September 2023 ANDA Filings Addressable Market Therapy ANDAs Size (US$ Bn)^ CNS 143 23.8 Aurobindo (Excl. Eugia Pharma 700 628 472 Eugia Pharma Specialities 600 500 180 156 450 160 Specialities Group) 500 400 350 140 120 ARV** 28 0.6 400 300 100 Group 59 41 250 CV
Slide 18: Global regulatory filing Details
Global regulatory filing Details As at As at As at As at As at As at As at As at As at As at Category Geography Approvals Mar 16 Mar 17 Mar 18 Mar 19 Mar 20 Mar 21 Mar 22 Mar 23 Jun 23 Sep 23 US* 398 429 478 541 586 639 727^ 774^ 814^ 817^ FA: 628, TA:32 Europe** 2,224 2,521 2,848 3,003 3,214 3,374
Slide 19: Thank You
Thank You BADDIGA Digitally signed by BADDIGAM ADI REDDY DN: c=IN, o=PERSONAL, title=7929, pseudonym=721d5e5f9caf4299ada369a85 ir@aurobindo.com 32fe7e6, For more information, contact: M ADI 2.5.4.20=1249e67e239a72d275591952aaf4f 0782b7b891e8cac84dffa9adbec758f170d, postalCode=500008, st=Telangana, s